Literature DB >> 15615540

Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells.

Dazhi Cen1, Daniel Brayton, Babbak Shahandeh, Frank L Meyskens, Patrick J Farmer.   

Abstract

The alcohol-abuse deterrent disulfiram (DSF) is shown to have a highly selective toxicity against melanoma in culture, inducing a largely apoptotic response, with much lower toxicity against several other cell lines. Melanoma cell lines derived from different stages (radial, vertical, and metastatic phase) were all sensitive to DSF treatment in vitro; melanocytes were only slightly affected. A required role of extracellular Cu is demonstrated for DSF toxicity. Low concentrations of DSF alone decreased the number of viable cells, and the addition of CuCl(2) significantly enhanced the DSF-induced cell death to less than 10% of control. Significantly, the intracellular Cu concentration of melanoma cells increased rapidly upon DSF treatment. Both the intracellular Cu uptake and the toxicity induced by DSF were blocked by co-incubation with bathocuproine disulfonic acid (BCPD, 100 muM), a non-membrane-permeable Cu chelator. Chemical studies demonstrated a complicated, extracellular redox reaction between Cu(II) and DSF, which forms the complex Cu(deDTC)(2) in high yield, accompanied by oxidative decomposition of small amounts of disulfiram. The Cu complex has somewhat higher activity against melanoma and is suggested to be the active agent in DSF-induced toxicity. The redox conversion of DSF was unique to Cu(II) and not engendered by the other common biological metal ions Fe(II or III), Mn(III), and Zn(II). The implications of this work are significant both in the possible treatment of melanoma as well as in limiting the known side-effects of DSF, which we propose may be diminished by cotreatment to decrease adventitious Cu.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15615540     DOI: 10.1021/jm049568z

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  69 in total

Review 1.  Novel metals and metal complexes as platforms for cancer therapy.

Authors:  Michael Frezza; Sarmad Hindo; Di Chen; Andrew Davenport; Sara Schmitt; Dajena Tomco; Q Ping Dou
Journal:  Curr Pharm Des       Date:  2010-06       Impact factor: 3.116

Review 2.  Cellular redox pathways as a therapeutic target in the treatment of cancer.

Authors:  Alberto J Montero; Jacek Jassem
Journal:  Drugs       Date:  2011-07-30       Impact factor: 9.546

Review 3.  New uses for old copper-binding drugs: converting the pro-angiogenic copper to a specific cancer cell death inducer.

Authors:  Di Chen; Q Ping Dou
Journal:  Expert Opin Ther Targets       Date:  2008-06       Impact factor: 6.902

4.  Disulfiram and Copper Ions Kill Mycobacterium tuberculosis in a Synergistic Manner.

Authors:  Alex G Dalecki; Mehri Haeili; Santosh Shah; Alexander Speer; Michael Niederweis; Olaf Kutsch; Frank Wolschendorf
Journal:  Antimicrob Agents Chemother       Date:  2015-06-01       Impact factor: 5.191

5.  Metal-binding effects of sirtuin inhibitor sirtinol.

Authors:  Eman A Akam; Ritika Gautam; Elisa Tomat
Journal:  Supramol Chem       Date:  2015-10-15       Impact factor: 1.688

6.  Combination of Disulfiram and Copper-Cysteamine Nanoparticles for an Enhanced Antitumor Effect on Esophageal Cancer.

Authors:  Yan Chang; Fang Wu; Nil Kanatha Pandey; Lalit Chudal; Meiying Xing; Xiaoli Zhang; Linh Nguyen; Xian Liu; J Ping Liu; Wei Chen; Zui Pan
Journal:  ACS Appl Bio Mater       Date:  2020-09-09

7.  Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer.

Authors:  Jennifer L Allensworth; Myron K Evans; François Bertucci; Amy J Aldrich; Richard A Festa; Pascal Finetti; Naoto T Ueno; Rachid Safi; Donald P McDonnell; Dennis J Thiele; Steven Van Laere; Gayathri R Devi
Journal:  Mol Oncol       Date:  2015-02-21       Impact factor: 6.603

8.  Ni(II), Cu(II), and Zn(II) diethyldithiocarbamate complexes show various activities against the proteasome in breast cancer cells.

Authors:  Boris Cvek; Vesna Milacic; Jan Taraba; Q Ping Dou
Journal:  J Med Chem       Date:  2008-09-25       Impact factor: 7.446

Review 9.  Redox-directed cancer therapeutics: molecular mechanisms and opportunities.

Authors:  Georg T Wondrak
Journal:  Antioxid Redox Signal       Date:  2009-12       Impact factor: 8.401

10.  ALDH isozymes downregulation affects cell growth, cell motility and gene expression in lung cancer cells.

Authors:  Jan S Moreb; Henry V Baker; Lung-Ji Chang; Maria Amaya; M Cecilia Lopez; Blanca Ostmark; Wayne Chou
Journal:  Mol Cancer       Date:  2008-11-24       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.